Francesca Avogadri-Connors

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype

Daniel Hirschhorn-Cymerman, Sadna Budhu, Shigehisa Kitano et al. · The Journal of Experimental Medicine · 2012 · 152 citations · Full text

Life Sciences, Immunology, Oncology +17

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Emiliano Cocco, F. Javier Carmona, Pedram Razavi et al. · Science Signaling · 2018 · 73 citations · Full text

Medicine, Oncology, Pharmacology +17

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody <i>in vivo</i>

Laurence Booth, Jane L. Roberts, Andrew Poklepovic et al. · Oncotarget · 2017 · 63 citations · Full text

Medicine, Oncology, Pharmacology +10

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

Dhivya R. Sudhan, Luis J. Schwarz, Ángel Guerrero‐Zotano et al. · Clinical Cancer Research · 2018 · 45 citations

Medicine, Oncology, Pharmacology +17

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

Laurence Booth, Jane L. Roberts, Andrew Poklepovic et al. · Cancer Biology & Therapy · 2017 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17